NAV

Sparteine

Identification

Generic Name
Sparteine
DrugBank Accession Number
DB06727
Background

Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.1

Type
Small Molecule
Groups
Experimental, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 234.387
Monoisotopic: 234.209598845
Chemical Formula
C15H26N2
Synonyms
  • (-)-sparteine
  • 6β,7α,9α,11α-pachycarpine
  • Esparteina
  • Lupinidine
  • Sparteina
  • Sparteine
  • Sparteinum
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbataceptThe metabolism of Sparteine can be increased when combined with Abatacept.
AbirateroneThe metabolism of Sparteine can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the arrhythmogenic activities of Sparteine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sparteine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Sparteine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Sparteine sulfateGQ3J2TLZ7ENot AvailableNot applicable

Categories

ATC Codes
C01BA04 — Sparteine
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
298897D62S
CAS number
90-39-1
InChI Key
SLRCCWJSBJZJBV-ZQDZILKHSA-N
InChI
InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1
IUPAC Name
(1S,2R,9S,10S)-7,15-diazatetracyclo[7.7.1.0^{2,7}.0^{10,15}]heptadecane
SMILES
[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2CCCC[C@]12[H]

References

Synthesis Reference

Bernd Hachmeister, "Process for the production of 17-hydroxysparteine by oxidation of sparteine with a permanganate." U.S. Patent US4237295, issued June, 1975.

US4237295
General References
  1. Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness. [Link]
KEGG Drug
D01041
KEGG Compound
C10783
PubChem Compound
168213
PubChem Substance
99443273
ChemSpider
559096
ChEBI
28827
ChEMBL
CHEMBL1908847
ZINC
ZINC000001408502
PharmGKB
PA452610
Wikipedia
Sparteine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)30.5 °CPhysProp
boiling point (°C)325 °CPhysProp
water solubility3040 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.931 mg/mLALOGPS
logP2.98ALOGPS
logP2.03Chemaxon
logS-2.4ALOGPS
pKa (Strongest Basic)9.16Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area6.48 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity71.82 m3·mol-1Chemaxon
Polarizability28.37 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9757
Blood Brain Barrier+0.9606
Caco-2 permeable+0.6725
P-glycoprotein substrateSubstrate0.55
P-glycoprotein inhibitor INon-inhibitor0.6379
P-glycoprotein inhibitor IINon-inhibitor0.8742
Renal organic cation transporterInhibitor0.7785
CYP450 2C9 substrateNon-substrate0.884
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6969
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9576
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9576
CYP450 3A4 inhibitorNon-inhibitor0.9518
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6629
Ames testNon AMES toxic0.6586
CarcinogenicityNon-carcinogens0.9538
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.4193 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7831
hERG inhibition (predictor II)Non-inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0pbd-5970000000-3ea71bbdd062fc818c1d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-ec5c956465fe0f7e725b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-d018297958d43527f657
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-84a24703942c09cbb365
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000j-7920000000-90fa1f4c2e84e3281510
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-b0a0299402252130c9a5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-5970000000-efe73c1220e05fe1e329
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-159.587248
predicted
DarkChem Lite v0.1.0
[M-H]-154.94597
predicted
DeepCCS 1.0 (2019)
[M+H]+159.670248
predicted
DarkChem Lite v0.1.0
[M+H]+157.34169
predicted
DeepCCS 1.0 (2019)
[M+Na]+160.047248
predicted
DarkChem Lite v0.1.0
[M+Na]+163.2825
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 2D6
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS, Brosen K: Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol. 2005 Aug;61(7):491-7. doi: 10.1007/s00228-005-0938-1. Epub 2005 Jul 16. [Article]
  2. Damkier P, Hansen LL, Brosen K: Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999 Dec;48(6):829-38. [Article]
  3. Flockhart Table of Drug Interactions [Link]

Drug created at August 18, 2010 20:01 / Updated at December 13, 2022 10:46